Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Protease inhibition

a protease and inhibitory technology, applied in the direction of enzyme inhibitors, peptide/protein ingredients, immunological disorders, etc., can solve the problems of a lack of specificity for particular adams, serious drawbacks of the methods which have been identified to date for inhibiting metalloproteases such as adams, and difficulty in predicting potential cleavage sites

Inactive Publication Date: 2010-11-18
CANCER RES TECH LTD
View PDF6 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016]In a further aspect, the invention provides a method for treating a subject suffering from a condition associated with ADAM protease activi

Problems solved by technology

So far, no consensus sequence on the substrate side has been reported, making prediction of potential cleavage sites difficult.
However, a number of the methods which have been identified to date for inhibiting metalloproteases such as ADAMs suffer from serious drawbacks.
For instance, hydroxamate compounds such as marimastat and batimastat (BB-94) are typically broad-spectrum inhibitors and suffer from a lack of specificity for particular ADAMs.
Consequently these compounds have shown deleterious side effects in clinical trials, which seriously restricts their usefulness as therapeutic agents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protease inhibition
  • Protease inhibition
  • Protease inhibition

Examples

Experimental program
Comparison scheme
Effect test

example 1a

Synthesis of Cyclic Peptides

[0101]In the following example, a series of peptides were synthesised in order to test their activity as inhibitors of ADAM proteases. The structures of the peptides are shown in Table 1 and FIG. 5.

[0102]Each peptide comprises 6 amino acid residues. Peptides P1 to P4 have the sequence RLSKDK, which is found in the integrin binding loop of the disintegrin domain of murine ADAM8. The KDK sequence of ADAM8 is at an equivalent position to the RGD sequence found in the integrin-binding loop of ADAM15. Peptides P1 to P3 are cyclic peptides comprising this motif, whereas P4 is a linear peptide with the KDK sequence at the C terminal. Each of P1 to P3 comprises a single β-amino acid, the position of which differs between the three peptides.

[0103]Each of peptides P5, P6 and P7 is a cyclic peptide which differs in sequence from peptide P1 at one amino acid position within the KDK motif found in P1. Each of P5 to P7 comprises a single β-amino acid residue at the sam...

example 1b

Synthesis of Cyclic Peptides

[0106]The peptides described in Example 1 may also be synthesised using the following method:

[0107]Cyclic peptides such as P1 were synthesised according to Malesevic et al., 2004, published in Journal of Biotechnology 112, 73-77. Briefly, linear peptides were synthesized according to an Fmoc-protocol with Wang resin as a solid support. In a typical experiment, each peptide coupling is done twice with 1.5 eq. Fmoc-amino acid (0.3M in DMF*), 1.5 eq. TBTU (0.3M in DMF) and 3 eq. DIPEA (0.6M in DMF). After washing with DMF the Fmoc group is cleaved with a solution of 2% piperidine and 2% DBU in DMF. Wang resin is used as the solid support which is preloaded with Fmoc-Asp-ODmb attached to the resin via the side chain functionality. After assembly of the peptide sequence, the terminal protecting groups (Fmoc at the N-terminus, Dmb at the C-terminus) are cleaved from the linear precursor. A solution of 1.0-3.0 eq. (relative to resin loading) of HATU in 3 mL DMF ...

example 2

Inhibiting Cell Adhesion Mediated by ADAM8 DC Domain Using Cyclic Peptides

[0109]In this example, peptides synthesised as described in example 1 were used to target cell adhesion mediated by the ADAM8 DC domain. A recombinant DC domain of ADAM8 was expressed and purified from E. coli and then coated onto cell culture plates. Cells over-expressing ADAM8 were then allowed to bind to the ADAM8 DC domain on the plates.

[0110]96-well plates were coated with 50 μg / ml of recombinant ADAM8 DC protein in PBS at 4° C. for 16 h. To express the recombinant DC domain of ADAM8, the cDNA fragment encoding the A8 DC domain was generated by PCR using Platinum™ Pfx polymerase (Invitrogen) with the following primers: DCE-A8f, 5′-GGT GGC CCT GTG TGT GGA AAC-3′ (SEQ ID NO:17); DCE-A8r, 5′-TAC ACA GTT GGG TGG TGC CCA-3′ (SEQ ID NO:18). The resulting cDNA fragment was cloned into the bacterial expression vector pTrcHis2 (Invitrogen) containing a C-terminal Myc and His6 tag. This vector was transformed into ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Structureaaaaaaaaaa
Lengthaaaaaaaaaa
Pharmaceutically acceptableaaaaaaaaaa
Login to View More

Abstract

The invention relates to a method for inhibiting an adam protease, comprising inhibiting binding to an integrin-binding loop of a disintegrin domain in the adam protease. Also provided are cyclic peptides which inhibit binding to an integrin-binding loop of an adam protease, as well as associated pharmaceutical compositions, uses and methods of treatment.

Description

FIELD OF THE INVENTION[0001]The present invention relates to methods and reagents for use in the field of inhibiting proteases, in particular proteases known as ADAMs (a disintegrin and metalloprotease domain). Inhibition of ADAMs according to the invention may be desirable in various in vitro and in vivo applications, including methods for treating diseases such as cancer.BACKGROUND OF THE INVENTION[0002]ADAMs (a disintegrin and metalloprotease) or MDCs (metalloprotease disintegrin cysteine-rich proteins) form a family of type I transmembrane proteins. Owing to their multidomain structure consisting of pro-, metalloprotease, disintegrin-like, cystein-rich, EGF-like, transmembrane and cytoplasmic domains, ADAMs are capable of four physiological functions: cell adhesion, cell fusion, cell signalling and proteolysis.[0003]ADAMs are implicated in physiological processes such as fertilisation, myogenesis and neurogenesis, and are also involved in a number of pathological processes by re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/48C12N9/99C12N9/50A61P31/00A61P37/08A61P29/00
CPCA61K38/00C07K5/0202C07K5/12C12N9/6489C07K5/126C07K7/56C07K14/8146C07K5/123A61K38/005A61K38/12A61P29/00A61P31/00A61P37/08C12Y304/24046C07K7/64C12Q1/37C07K7/06C07K16/40C07K2317/76
Inventor BARTSCH, JOERGKOLLER, GARRIT
Owner CANCER RES TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com